Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), Route of Administration (Intravenous, Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Size
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to witness significant growth during the forecast period. The rise in the occurrence of harmful habits such as excessive smoking, excessive sedentariness, and consumption of pollutants present in the air in urban centers has resulted in a growing incidence of autoimmune diseases since the last few years. Numerous potential drugs are in the pipeline for treating chronic inflammatory demyelinating polyneuropathy (CIDP). Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Data Bridge Market Research analyses a growth rate in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market in the forecast period 2022-2029. The expected CAGR of global chronic inflammatory demyelinating polyneuropathy (CIDP) market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 1.51 billion in 2021, and it would grow upto USD 2.69 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), Route of Administration (Intravenous, Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Chronic inflammatory demyelinating polyneuropathy is a type of neurological disorder wherein the body immune system attacks myelin which is an important part of the nervous system. This can cause pain, loss of sensation, chronic fatigue, impaired ability, and other problems. Several treatments can be used to treat this disease such as intravenous immunoglobulin, plasmapheresis, physiotherapy and others. This disease occurrence is rising and important diagnostic procedures and treatments will boost the growth of the market.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics
Drivers
- Increasing Drug Approvals
Growing drug approvals by several regulatory authorities is projected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. FDA approval for Privigen, an immunoglobulin therapy for treating chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. Additionally, in March 2018, CSL Behring again received U.S. FDA approval for Hizentra. It is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. The approval was based on the results of phase III clinical trial. These factors are expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
- Growing Advanced Technologies
The rising introduction of several advanced technologies in diagnostic tools for chronic inflammatory demyelinating polyneuropathy (CIDP) disorder is anticipated to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in July 2018, according to National Centre for Biotechnology Information (NCBI) reports, a technique called multifocal visional evoked potential is meant to diagnose CIDP and can detect abnormalities in the optic nerve fiber, thus ensuring higher accuracy in diagnosis.
Opportunities
- Increasing Development of Drugs
There are numerous potential drugs in the pipeline that are used for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). For instance, in January 2016, Shire plc, began clinical trials of HyQvia for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. It is a type of intravenous immunoglobulin therapy approved for primary immunodeficiency treatment and is presently in phase III of clinical trials. All these factors are also contributing in the growth of the market.
- Growing Autoimmune Disorders
As per the American Autoimmune Related Diseases Association, autoimmune disorders affect around 50 million Americans in 2017. Research and development in plasma-derived therapies will likely boost the expansion in the market value of chronic inflammatory demyelinating polyneuropathy. Therefore, this set of population requires high-end use of therapeutics which in return creates more opportunities for the market growth.
Restraints/Challenges
- Failure of Clinical Drugs
Failure of the drugs in the late stages of clinical trials has impeded the chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, drugs such as Fingolimod, and Acthar gel are developed for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) which failed in the clinical trials in 2016, and 2018, respectively. These drug failures were associated with major adverse events such as extreme pain, fluid retention, hypertension, alteration in glucose tolerance, and behavioral and mood changes. Thus, it hampered the market growth.
- High Cost of Treatments
The cost for diagnosis and treatment of demyelinating disease is very high. According to the Institute for Clinical and Economic Review (ICER) record, in 2019, the average annual cost of a rare disease treatment for each treated patient was $32,000, ranging from $6,000 to $500,000 per year. High cost for treatment and diagnosis may restrict the demyelinating diseases therapeutics market growth over the forecast period 2022-2029.
This global chronic inflammatory demyelinating polyneuropathy (CIDP) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic inflammatory demyelinating polyneuropathy (CIDP) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
With respect to the pandemic, substantial segments of the medical industry have shifted to telemedicine in order to make patient visits more suitable. Based on a video visit during the COVID-19 outbreak, patients who were subsequently confirmed as having CIDP and managed with intravenous immunoglobulins greatly improved clinical examination and electrodiagnostic tests. Telemedicine cannot be used to conduct neuromuscular assessment because of technical restrictions. Thus, COVID-19 greatly impacted the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Scope
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is segmented on the basis of treatment, diagnosis, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Intravenous Immunoglobulin
- Corticosteroids
- Aristocort
- Bubbli-Pred
- Celestone
- Plasmapheresis
- Physiotherapy
- Others
Diagnosis
- Electrodiagnostic Testing
- Nerve Conduction
- EMG
- Spinal Fluid Analysis
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional Analysis/Insights
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is analyzed and market size insights and trends are provided by treatment, diagnosis, route of administration,end-user, distribution channel as referenced above.
The major countries covered in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the high-income of the countries and favorable reimbursement.
Asia-Pacific is dominating the market due to rise in the research and development associated with plasma-derived medicines and rise in the government support via awareness programs and drug approvals in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Analysis
The chronic inflammatory demyelinating polyneuropathy (CIDP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Key players operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Actelion Pharmaceuticals Ltd (Switzerland)
SKU-